- Home
- YI vs ACRV Comparison
YI vs ACRV Comparison
Compare YI & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- ACRV
- Stock Information
- Founded
- YI 2010
- ACRV 2018
- Country
- YI China
- ACRV United States
- Employees
- YI N/A
- ACRV N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- YI Consumer Staples
- ACRV Health Care
- Exchange
- YI Nasdaq
- ACRV Nasdaq
- Market Cap
- YI 69.4M
- ACRV 73.5M
- IPO Year
- YI N/A
- ACRV 2022
- Fundamental
- Price
- YI $8.61
- ACRV $2.03
- Analyst Decision
- YI
- ACRV Strong Buy
- Analyst Count
- YI 0
- ACRV 6
- Target Price
- YI N/A
- ACRV $21.80
- AVG Volume (30 Days)
- YI 34.8K
- ACRV 170.2K
- Earning Date
- YI 03-20-2025
- ACRV 05-13-2025
- Dividend Yield
- YI N/A
- ACRV N/A
- EPS Growth
- YI N/A
- ACRV N/A
- EPS
- YI N/A
- ACRV N/A
- Revenue
- YI $1,973,017,082.00
- ACRV N/A
- Revenue This Year
- YI N/A
- ACRV N/A
- Revenue Next Year
- YI N/A
- ACRV N/A
- P/E Ratio
- YI N/A
- ACRV N/A
- Revenue Growth
- YI N/A
- ACRV N/A
- 52 Week Low
- YI $0.41
- ACRV $2.02
- 52 Week High
- YI $11.35
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- YI 49.50
- ACRV 21.46
- Support Level
- YI $9.13
- ACRV $5.00
- Resistance Level
- YI $10.52
- ACRV $5.65
- Average True Range (ATR)
- YI 0.85
- ACRV 0.44
- MACD
- YI -0.21
- ACRV -0.37
- Stochastic Oscillator
- YI 36.03
- ACRV 0.28
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.